Small Company Offering and Sale of Securities Without Registration (d)
February 01 2021 - 4:19PM
Edgar (US Regulatory)
o
NoneEntity Type | 0001638287 | NeuroBo Therapeutics, Inc. Gemphire Therapeutics Inc. |
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other |
| Name of Issuer |
NeuroBo Pharmaceuticals, Inc. |
| Jurisdiction of Incorporation/Organization |
| DELAWARE |
| |
| Year of Incorporation/Organization |
| |
x
| Over Five Years Ago |
| |
o
| Within Last Five Years (Specify Year) | |
| |
o
| Yet to Be Formed | |
| 2. Principal Place of Business and Contact Information |
| Name of Issuer | |
| NeuroBo Pharmaceuticals, Inc. | |
| Street Address 1 | Street Address 2 |
| 200 BERKELEY ST. | FL 19 |
| City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
| BOSTON | MASSACHUSETTS | 02116 | (857) 702-9600 |
| Last Name | First Name | Middle Name |
| Kang | Richard | J. |
| Street Address 1 | Street Address 2 |
| 200 Berkeley Street, Office 19th Floor | |
| City | State/Province/Country | ZIP/Postal Code |
| Boston | MASSACHUSETTS | 02116 |
| Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Bakshi | Akash | |
| Street Address 1 | Street Address 2 |
| 200 Berkeley Street, Office 19th Floor | |
| City | State/Province/Country | ZIP/Postal Code |
| Boston | MASSACHUSETTS | 02116 |
| Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Shannon | Nicola | |
| Street Address 1 | Street Address 2 |
| 200 Berkeley Street, Office 19th Floor | |
| City | State/Province/Country | ZIP/Postal Code |
| Boston | MASSACHUSETTS | 02116 |
| Relationship: |
x
| Executive Officer |
o
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Kim | Na Yeon | |
| Street Address 1 | Street Address 2 |
| 200 Berkeley Street, Office 19th Floor | |
| City | State/Province/Country | ZIP/Postal Code |
| Boston | MASSACHUSETTS | 02116 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Groves | Jason | |
| Street Address 1 | Street Address 2 |
| 200 Berkeley Street, Office 19th Floor | |
| City | State/Province/Country | ZIP/Postal Code |
| Boston | MASSACHUSETTS | 02116 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Oh | Jeong Gyun | |
| Street Address 1 | Street Address 2 |
| 200 Berkeley Street, Office 19th Floor | |
| City | State/Province/Country | ZIP/Postal Code |
| Boston | MASSACHUSETTS | 02116 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Salsbury | Michael | |
| Street Address 1 | Street Address 2 |
| 200 Berkeley Street, Office 19th Floor | |
| City | State/Province/Country | ZIP/Postal Code |
| Boston | MASSACHUSETTS | 02116 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Swirsky | Douglas | J. |
| Street Address 1 | Street Address 2 |
| 200 Berkeley Street, Office 19th Floor | |
| City | State/Province/Country | ZIP/Postal Code |
| Boston | MASSACHUSETTS | 02116 |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
|
o
| Agriculture | | Health Care |
o
| Retailing |
| | Banking & Financial Services | |
x
| Biotechnology |
o
| Restaurants |
| |
o
| Commercial Banking | |
o
| Health Insurance | | Technology |
| |
o
| Insurance | |
o
| Hospitals & Physicians | |
o
| Computers |
| |
o
| Investing | |
o
| Pharmaceuticals | |
o
| Telecommunications |
| |
o
| Investment Banking | |
o
| Other Health Care | |
o
| Other Technology |
| |
o
| Pooled Investment Fund
| | | | | Travel |
| |
o
| Other Banking & Financial Services |
o
| Manufacturing | |
o
| Airlines & Airports |
| | Real Estate | |
o
| Lodging & Conventions |
| |
o
| Commercial | |
o
| Tourism & Travel Services |
| |
o
| Construction | |
o
| Other Travel |
| |
o
| REITS & Finance |
o
| Other |
| |
o
| Residential | |
| |
o
| Other Real Estate | |
|
o
| Business Services | |
| | Energy | |
| |
o
| Coal Mining | |
| |
o
| Electric Utilities | |
| |
o
| Energy Conservation | |
| |
o
| Environmental Services | |
| |
o
| Oil & Gas | |
| |
o
| Other Energy | |
| Revenue Range | Aggregate Net Asset Value Range |
|
o
| No Revenues |
o
| No Aggregate Net Asset Value |
|
o
| $1 - $1,000,000 |
o
| $1 - $5,000,000 |
|
o
| $1,000,001 - $5,000,000 |
o
| $5,000,001 - $25,000,000 |
|
o
| $5,000,001 - $25,000,000 |
o
| $25,000,001 - $50,000,000 |
|
o
| $25,000,001 - $100,000,000 |
o
| $50,000,001 - $100,000,000 |
|
o
| Over $100,000,000 |
o
| Over $100,000,000 |
|
x
| Decline to Disclose |
o
| Decline to Disclose |
|
o
| Not Applicable |
o
| Not Applicable |
| 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
|
o
| Rule 504(b)(1) (not (i), (ii) or (iii)) |
o
| Rule 505 |
|
o
| Rule 504 (b)(1)(i) |
x
| Rule 506(b) |
|
o
| Rule 504 (b)(1)(ii) |
o
| Rule 506(c) |
|
o
| Rule 504 (b)(1)(iii) |
o
| Securities Act Section 4(a)(5) |
| |
o
| Investment Company Act Section 3(c) |
|
x
| New Notice | Date of First Sale | 2021-01-21 |
o
| First Sale Yet to Occur |
| Does the Issuer intend this offering to last more than one year? |
o
| Yes |
x
| No |
| 9. Type(s) of Securities Offered (select all that apply) |
|
o
| Pooled Investment Fund Interests |
x
| Equity |
|
o
| Tenant-in-Common Securities |
o
| Debt |
|
o
| Mineral Property Securities |
x
| Option, Warrant or Other Right to Acquire Another Security |
|
x
| Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security |
o
| Other (describe) |
| | |
| 10. Business Combination Transaction |
| Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? |
o
| Yes |
x
| No |
| |
| Clarification of Response (if Necessary) | |
| |
| Minimum investment accepted from any outside investor | $ 0 USD |
| Recipient | Recipient CRD Number |
o
| None |
| H.C. Wainwright & Co., Inc. | 375 |
| (Associated) Broker or Dealer |
x
| None | (Associated) Broker or Dealer CRD Number |
x
| None |
| | |
| Street Address 1 | Street Address 2 |
| 430 Park Avenue | 4th Floor |
| City | State/Province/Country | ZIP/Postal Code |
| New York | NEW YORK | 10022 |
| State(s) of Solicitation |
o
| All States |
o
| Foreign/Non-US |
ILLINOIS
NEVADA
NEW YORK
NEW JERSEY
CALIFORNIA
|
| 13. Offering and Sales Amounts |
| Total Offering Amount | $ 10000000 USD |
o
Indefinite |
| Total Amount Sold | $ 10000000 USD | |
| Total Remaining to be Sold | $ 0 USD |
o
Indefinite |
| |
| Clarification of Response (if Necessary) |
| Excludes proceeds totaling up to $15,075,000 from the exercise of the warrants. |
|
o
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
| |
| | Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 10 |
| 15. Sales Commissions & Finders’ Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
| Sales Commissions | $ 700000 USD |
o
| Estimate |
| Finders' Fees | $ 0 USD |
o
| Estimate |
| |
| Clarification of Response (if Necessary) |
| |
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
| | $ 0 USD |
o
NeuroBo Pharmaceuticals (NASDAQ:NRBO) Historical Stock Chart From Jun 2024 to Jul 2024
NeuroBo Pharmaceuticals (NASDAQ:NRBO) Historical Stock Chart From Jul 2023 to Jul 2024
See More Message Board Posts
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|